{
  "docId": "019de072-0fef-7225-bee8-4eafefc8a1ee",
  "docSlug": "7f14a86c142f5693f0e80c8dcf59a0d2",
  "documentTitle": "23andMe | Investor Presentation Deck | 63 slides",
  "authorId": "23andme",
  "authorName": "23andMe",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 48,
  "pageCount": 63,
  "prevPage": 47,
  "nextPage": 49,
  "slideType": "solution",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-0fef-7225-bee8-4eafefc8a1ee/48",
  "deckHref": "/decks/019de072-0fef-7225-bee8-4eafefc8a1ee",
  "deckJsonHref": "/decks/019de072-0fef-7225-bee8-4eafefc8a1ee.json",
  "deckAnchorHref": "/decks/019de072-0fef-7225-bee8-4eafefc8a1ee#slide-48",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.9,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "list",
      "text": "CD200R1 is an immune checkpoint with a strong I/O signature in three components of the pathway\nCD200 is highly expressed in a subset of human cancers and its binding to CD200R1 decreases the ability of T cells to recognize and kill cancer cells\n23ME'610 is a potent, effectorless, monoclonal antibody against CD200R1 that has the potential to restore T-cell killing of cancer cells\nThe Phase 1 dose escalation study of 23ME'610 in patients with advanced solid malignancies was initiated in January 2022\nFurther evaluation of 23ME'610 will occur in expansion cohorts for adolescents and for specific disease areas",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e9a677ab-4b79-426b-9a7c-ce29a66ee6d1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "23ME'610 Targeting CD200R1: A Genetically-Validated Approach to Anti-Cancer Therapy",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "723740a5-0834-49e7-99bf-d8d3af825c9f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}